. Histone PTMs (or marks) can serve as the docking sites for effector proteins ('readers') that specifically recognize them [3] [4] [5] . By recruiting 'readers' to the chromatin, histone PTMs signal the downstream biological events (for example, gene transcription, DNA replication and repair), underlying one of the key cellular mechanisms for epigenetic regulation 6, 7 . Given their importance in maintaining normal cell physiology, improper 'writing' , 'erasing' and 'reading' of histone modifications have been implicated in many human diseases, such as cancer 8, 9 . The epigenetic protein families have therefore emerged as promising targets for drug discovery 10, 11 . The development of chemical epigenetic modulators, mostly inhibitors, has provided useful tools to probe the regulatory mechanisms and biological significances of histone PTMs. More importantly, a collection of inhibitors have become potential therapeutic agents for the treatment of diseases associated with abnormal epigenetic regulation.
Early endeavors targeting the epigenome have focused on histone-modifying enzymes, leading to the development of potent and selective inhibitors 12 . Several histone deacetylase (HDAC) inhibitors have even been approved for clinical uses (for example, vorinostat) 13 . The inhibitor development for epigenetic 'readers' has been a relatively slow-paced process. One possible reason could be that the recognition patterns of histone PTMs by the readers commonly involve shallow binding pockets or even appear as surface groove recognitions. The affinities for such PTM-mediated interactions are normally weak, and the binding pockets are seldom ideal for inhibitors with nanomolar activities. In addition, designing inhibitors that target the interfaces with a large area is much more challenging than targeting an enzyme with well-defined catalytic residues. Bromodomain (BrD), which recognizes lysine acetylation (Kac, Supplementary Fig. 1a ), is one of the epigenetic 'readers' that has been extensively explored for inhibitor development 14 . A set of BrD inhibitors are now in different stages of clinical trials for the treatment of human diseases, including cancer, atherosclerosis, and diabetes 15, 16 . Besides the BrDs, the YEATS domain was identified as a novel 'reader' of Kac 17, 18 . The human genome encodes four YEATS domaincontaining proteins: AF9, ENL, YEATS2, and GAS41 19 . Unlike the BrDs with end-closed binding cavities, the YEATS domains coordinate the acetyllysine with an end-open aromatic 'sandwich' cage shaped by two conserved aromatic residues 17 . Notably, the tunnellike feature of the end-open cage also enables the YEATS domains to recognize the histone lysine crotonylation (Kcr, Supplementary  Fig. 1a ) marks [20] [21] [22] [23] , whose acyl chain is two carbons longer than that of Kac. Moreover, the conjugated O = C− C = C moiety of the crotonyl group forms a unique π -π -π stacking with the two conserved aromatic residues, which considerably enhances the binding affinity, suggesting a preference of the YEATS domain for Kcr over Kac. Recently, the AF9 YEATS domain was found to mediate active transcription through 'reading' the histone Kac and Kcr marks 17, 20 . The YEATS-dependent association of ENL with acetylated histone H3 was reported to be essential for oncogenic gene expression in aggressive leukemia 24, 25 . By 'reading' the H3K27ac mark, YEATS2 regulates transcriptional programs essential for tumorigenesis of non-small-cell lung cancer 26 . Despite these discoveries, we still lack comprehensive understanding of the functional outcomes of YEATS-Kac/Kcr interactions in the epigenetic regulation. The development of YEATS domain inhibitors should provide useful tools to fill such a knowledge gap, as well as offer potential therapeutic agents targeting the YEATS domain.
Here we describe the structure-guided development of, to the best of our knowledge, the first class of YEATS domain inhibitors by targeting the π -π -π stacking in the aromatic 'sandwich' cage.
Structure optimization led to the identification of AF9 YEATS-and ENL YEATS-selective inhibitors with potent submicromolar activity. We showed that an ENL YEATS-selective inhibitor, XL-13m (1 ), engaged with endogenous ENL. Using MOLM-13 cells, an MLLrearranged acute leukemia cell line, we also demonstrated that XL-13m can be used as a chemical probe to interrogate the YEATSdependent role of ENL in regulating gene transcription.
results
Targeting YEATS domain by enhanced π-π-π stacking. Our design of YEATS domain inhibitors was enlightened by the unique π -π -π stacking in the crystal structure of the AF9 YEATS-H3K9cr complex 20 . In this structure, the conjugated crotonyl group inserts into the aromatic 'sandwich' cage formed by the two conserved aromatic residues, F59 and Y78 ( Fig. 1a and Supplementary  Fig. 1b ). This unique π -π -π interaction underlies why the binding affinity of YEATS domains to Kcr is normally 2− 5-fold higher than that to Kac 27 . We reasoned that replacing the crotonyl group with an expanded π system may further enhance the interaction. Therefore, to target the YEATS domains, we designed and synthesized a series of decapeptides, XL-01 to XL-16 (2 to 17 , respectively; Supplementary Fig. 1c ), derived from histone H3 (residues 4-13) with Lys 9 carrying π system-containing functional groups.
We evaluated the binding ability of the synthesized decapeptides toward the YEATS domains using a competitive photo-cross-linking assay [28] [29] [30] . The assay relied on a photoaffinity probe (photo-H3K9cr, Fig. 1b ) that covalently captures the YEATS domains upon UV irradiation. Photo-H3K9cr was derived from a H3 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] K9cr peptide in which the Thr11 was replaced by a diazirine-containing photoreactive amino acid (photo-Leu). The probe also had a terminal alkyne-containing amino acid (propargylglycine) to enable bioorthogonal conjugation of fluorescence tags for detection of the captured proteins.
If a tested decapeptide could compete with photo-H3K9cr to occupy the same Kcr-binding sites of the YEATS domains, the labeling of YEATS domains would be inhibited (Fig. 1c) . As shown in Fig. 1d , photo-H3K9cr robustly labeled AF9 YEATS in a concentrationdependent manner. This labeling was competed off by the native H3K9cr peptide with an IC 50 of 6.0 μ M ( Supplementary Fig. 2a) , which is in a line with its dissociation constant (K d = 14.7 μ M, Supplementary Fig. 3a,b) determined by isothermal titration calorimetry (ITC). We then tested the decapeptides XL-01 to XL-16. Strikingly, 6 out of the 16 decapeptides showed a lower IC 50 than the native H3K9cr peptide toward AF9 YEATS ( Supplementary  Fig. 2b-q) . The two decapeptides carrying a 2-furancarbonyl side chain (XL-07, Fig. 1e ) and a 5-oxazolecarbonyl side chain (XL-13, Fig. 1e ) showed the highest inhibition potencies with IC 50 values of 1.3 and 0.74 μ M, respectively ( Fig. 2a; Supplementary Fig. 2h,n) . In contrast, a control decapeptide, XL-17 (18 , Fig. 1e ), lacking a conjugated π system displayed a very weak inhibitory effect ( Fig. 2a and Supplementary Fig. 2r ), highlighting the crucial role of the expanded π system for targeting the YEATS domains. Further ITC measurements showed that the replacement of the crotonyl group Fig. 2b and Supplementary Fig. 3b ) and 5-oxazolecarbonyl (XL-13, Fig. 2c and Supplementary Fig. 3b ) led to 4.5-and 14.7-fold binding enhancement, respectively.
Toward minimal length and higher potency. We next sought out to optimize the developed inhibitors toward a shorter length and higher potency. In the AF9 YEATS-H3K9cr complex, the H3 Arg8 and Lys9 residues provide the key contacts and dominate the interaction with the YEATS domain ( Supplementary Fig. 1b ) 20 . We therefore synthesized a dipeptide, XL-07a (19 ) , with the RK signature motif (Supplementary Fig. 4a ) and added to it the surrounding residues one by one to generate another seven inhibitors, XL-07b to XL-07h (20 to 26 , respectively; Supplementary Fig. 4a ). Compared to XL-07, the dipeptide XL-07a showed a significantly reduced inhibitory activity ( Supplementary Fig. 4b,c) . Adding the residues at the N-terminus of XL-07a gradually restored the inhibitors' potency. The pentapeptide XL-07h with the QTARK sequence exhibited activity comparable to XL-07(IC 50 = 4.5 μ M; Supplementary Fig. 4d ). In contrast, the C-terminal residues of the RK motif negatively impacted their interactions with AF9 YEATS (Supplementary Fig. 4b,c) . Capping the N-terminus of the pentapeptide XL-07h with a hydrophobic carboxybenzyl (Cbz) group produced a more potent inhibitor, XL-07i (27 , IC 50 
Figs. 1e and 2d,e; Supplementary  Figs. 3b and 4e ). Replacing the 2-furancarbonyl group in XL-07i with 5-oxazolecarbonyl group generated another inhibitor, XL-13a (28 , Fig. 1e) , with slightly strengthened potency (IC 50 Fig. 2d,f; Supplementary Figs. 3b and 4f ).
Crystallographic studies of AF9 YEATS-inhibitor complex. To study the molecular basis underlying AF9 YEATS inhibition, we determined the crystal structure of AF9 YEATS bound to XL-07i at 1.9 Å resolution (Supplementary Table 1 ). In the complex, XL-07i stretches along the surface formed by loops L4, L6, and L8 of AF9 YEATS (Fig. 3a) . The planar 2-furancarboyl group inserts into the same Kac/Kcr-binding aromatic 'sandwich' cage and parallels well with the aromatic rings of AF9 F59 and Y78, forming an expected π -π -π stacking (Fig. 3b) . Compared with the Kcr accommodation, the aromatic cage is almost identically arranged to coordinate the 2-furancarbonyl moiety of XL-07i, except for a slight conformational change of the F28 phenyl ring (Fig. 3c) . The substitution of crotonyl by 2-furancarbonyl expands the interaction surface area from 174 Å 2 to 235 Å 2 , filling the unoccupied space in the binding pocket and ensuring a snug encapsulation of the five-membered furan ring (Fig. 3d,e) . Besides retaining the conserved hydrogen Competitor (μM) Time (min) For all the competitive photo-cross-linking assays, after UV irradiation, the photo-H3K9cr-labeled protein was conjugated to rhodamine-N 3 and visualized by in-gel fluorescence scanning. The fluorescence intensity of each band was quantified by ImageJ. All curves were normalized between 100% and 0% at the highest and lowest fluorescence intensities, respectively. Data are reported as mean of two independent experiments. All the ITC measurements were repeated independently for three times with similar results. Thermodynamic parameters are listed in Supplementary Fig. 3b . Uncropped gels are provided in Supplementary Fig. 12 . bonding interactions in crotonylamide recognition, the furan oxygen atom forms one more hydrogen bond with the side chain hydroxyl group of AF9 S58, further stabilizing the 2-furancarbonyl group (Fig. 3f,g ). The residues other than the modified lysine in XL-07i form extensive polar and hydrophobic contacts with AF9 YEATS (Fig. 3h,i) , strengthening the protein-inhibitor interaction. Notably, the geometry between the XL-07i Cbz group and the H107 and H111 residues in loop L8 of AF9 YEATS suggests that the phenyl ring of Cbz forms parallel-displaced (with H111) and edge-to-face (with H107) π stackings with the two imidazole rings (Fig. 3j,k) . These stackings are likely to be the reason that the addition of the N-terminal Cbz group largely increased the inhibitory potency of the inhibitors. An in silico modeling study on AF9 YEATS-XL-13a interaction revealed that the replacement of the furan ring with an oxazole ring contributes additional contacts between the inhibitor and the protein. Facilitated by the nitrogen atom in the oxazole ring, XL-13a takes part in the hydrogen bonding network between G77 and Y78 of AF9 and a cluster of structural water molecules nearby ( Supplementary Fig. 5a ). Additionally, the conformation of the 5-oxazolecarbonyl group points the nitrogen atom to F28 of AF9 in a manner that suggests a moderate lone pair-π interaction ( Supplementary Fig. 5b ). The water-mediated hydrogen bonding and the lone pair-π interaction make the 5-oxazolecarbonyl group more favorable to the AF9 YEATS than 2-furancarbonyl group, leading to an enhanced inhibitory activity.
Developing ENL YEATS-selective inhibitors.
We next asked whether the developed inhibitors could target the other YEATS domains. The competition assays against YEATS domains of ENL, YEATS2, and GAS41 showed that XL-07i and XL-13a were more selective toward the YEATS domains of AF9 and ENL compared to YEATS2 and GAS41 ( Fig. 4a; Supplementary Fig. 6a-h ). Given the high sequence and structure similarity between AF9 and ENL YEATS domains, it was expected that the AF9 YEATSbinding inhibitors may also interact with ENL YEATS. However, it was interesting to learn that, compared with AF9 YEATS, XL-07i and XL-13a exhibited 5-and 2.9-fold lower potency against ENL YEATS, respectively. This observation demonstrated the possibility to develop inhibitors that distinguish these two similar YEATS domains. It was recently reported that ENL, but not AF9, participated in the regulation of oncogenic gene transcription in acute leukemia through 'reading' the histone Kac marks by its YEATS domain 24, 25 . We therefore sought to develop inhibitors that selectively target the ENL YEATS.
The ENL YEATS domain was found to have a slightly higher affinity for binding H3K27cr than H3K9cr 20 . We thus prepared peptides based on the amino acids surrounding the K27 site and with the 5-oxazolecarbonyl π system installed at this lysine residue. By varying the length of the flanking sequence, another 14 oligopeptides, XL-13b to XL-13o (29 to 41 , respectively; Supplementary Fig. 7a ), containing the signature RK motif were synthesized and screened for their inhibitory activities against ENL YEATS ( Supplementary  Fig. 7b,c) . Interestingly, unlike the observation in AF9 YEATS inhibition, the dipeptide XL-13l (IC 50 = 3.3 μ M, Supplementary  Fig. 7d ) with only the RK signature motif showed even higher inhibitory efficiency than the undecapeptide XL-13b (IC 50 = 6.9 μ M, Supplementary Fig. 7e ), indicating the dominant contribution of these two key residues in the ENL YEATS recognition. Further addition of the N-terminal residues achieved improved inhibition of ENL YEATS for the tripeptide XL-13m (IC 50 = 0.56 μ M) and tetrapeptide XL-13n (IC 50 = 0.28 μ M) ( Fig. 4b,c ; Supplementary  Fig. 8a,b) . In contrast to the AF9 YEATS-selective inhibitors XL-07i and XL-13a, these two new inhibitors showed a preference for targeting ENL YEATS, as their inhibitions against AF9 YEATS were 4.5-and 6.1-fold weaker (for XL-13m, IC 50 = 2.5 μ M; for XL-13n, IC 50 = 1.7 μ M; Fig. 4c; Supplementary Fig. 8c,d) . Furthermore, we also examined the developed YEATS inhibitors against other two human YEATS domains (YEATS2 and GAS14), Kac 'readers' (BrDs of CBP, BAZ2B, and BRD4), Kac/Kcr 'eraser' (Sirt3), and 'readers' of lysine methylation marks (SPIN1 and ING2). The data suggest that these inhibitors are selective to AF9 and ENL but have little inhibitory effects toward other tested epigenetic regulators. (Fig. 4d ; Supplementary Figs. 8e-h and 9a,b) .
Engagement of XL-13m with endogenous ENL. We next examined the ability of the developed inhibitors to target endogenous ENL in cells. Given the comparable potency of the tripeptide XL-13m and tetrapeptide XL-13n, we chose to further study XL-13m, which was expected to have better cell permeability. To this end, we carried out a competitive pull-down experiment in which the cell nuclear extracts were photo-cross-linked by photo-H3K9cr in the presence or absence of XL-13m. The cross-linked proteins were then conjugated with biotin azide (biotin-N 3 ) via click chemistry, which was followed by streptavidin enrichment, SDS-PAGE, and immunoblotting analysis. As shown in Fig. 5a , photo-H3K9cr successfully cross-linked and enriched endogenous AF9 and ENL proteins from the nuclear extracts of HEK 293 T cells. XL-13m, at a concentration as low as 2 μ M, inhibited around 50% of the photo-H3K9cr-induced enrichment of endogenous ENL. In contrast, the enrichment of AF9 was not significantly affected (~3% inhibition). At high concentrations of 20 or 50 μ M, XL-13m caused more than 90% inhibition on ENL enrichment, but less than 30% on the AF9 (Fig. 5b) . This result suggests that whereas the AF9 YEATS-Kcr interaction could be slightly affected by XL-13m, the ENL YEATS-Kcr interaction was much more sensitive to XL-13m treatment. The competitive pull-down assays were also performed using nuclear extracts of another two cell lines: HeLa S3 and MLL-rearranged leukemia cells MOLM-13 that stably express Flag-tagged ENL at a level equivalent to the endogenous ENL protein 24 ( Supplementary Fig. 10 ). As expected, the photo-H3K9cr-induced enrichment of ENL was significantly inhibited by XL-13m, with little effect on the enrichment of AF9 (Supplementary Fig. 11 ). These results agree well with the observed selectivity of XL-13m toward ENL using the recombinant YEATS domains.
We next applied the cellular thermal shift assay (CETSA) 31, 32 to examine whether XL-13m was cell permeable and could target ENL in living cells. Three leukemia cell lines-MOLM-13, MV4;11, and HEL-were treated with XL-13m and then heated at different temperatures to denature and precipitate proteins. The inhibitor-bound ENL should have better thermal stability and thus resist the high temperature-induced precipitation. Soluble proteins were extracted by freez-thaw cycle and subjected to immunoblotting analysis. Indeed, we detected a higher abundance of soluble ENL proteins in XL-13m-treated samples at higher temperatures (55 °C, 57 °C, and 59 °C) compared to the untreated ones (Fig. 5c) . On the contrary, the thermal stability of endogenous AF9 showed almost no difference with or without XL-13m treatment (Fig. 5d) . The CETSA results in three different cell lines clearly demonstrated that XL-13m can enter cells and engage with the endogenous ENL, but not AF9, under the tested condition.
XL-13m perturbs the recruitment of ENL onto chromatin. ENL was known to regulate the leukemogenic gene transcription through its YEATS domain-dependent association with chromatin 24, 25 . We next examined whether XL-13m could perturb the ENL-chromatin interaction and thereby modulate gene transcription. Using chromatin immunoprecipitation and quantitative PCR (ChIP-qPCR), we detected the decreases in the abundance of ENL at several selected genes related to leukemia initiation, including HOXA10, MYB, MYC and MEIS1, in the MOLM-13 cells treated with XL-13m, suggesting that engagement of the inhibitor could indeed prevent the enrichment of ENL on its targeted genes (Fig. 6a) . Furthermore, we observed a significant loss in the transcription levels of these pro-leukemogenesis genes upon XL-13m treatment (Fig. 6b) , which is consistent with the unloading of the ENL from chromatin. Our results suggested that the XL-13m-induced YEATS inhibition blocked the chromatin association of ENL, suppressing the transcription of the oncogenes HOXA10, MYB, MYC and MEIS1 in acute leukemia cells. The observation agrees with the recent discoveries that ENL downregulation or loss-of-Kac-binding mutation in ENL YEATS led to transcription defects of its target genes 24, 25 . XL-13m synergizes with BET and DOT1L inhibition. Finally, we sought to probe the regulatory roles of ENL in gene transcription using XL-13m. As a core component of the super elongation complex (SEC), ENL has been suggested to participate in transcription control together with other SEC members such as the positive transcription elongation factor (P-TEFb) 24 . Through direct association with P-TEFb, bromodomain and extraterminal domain (BET) family members (for example, BRD4) serve as positive regulators of transcription 33, 34 . A recent RNA-seq study showed that the depletion of ENL or the mutation disrupting ENL YEATS-chromatin association in leukemia cells potentiated the BET inhibitor JQ1-induced transcriptional variations 24 . By analyzing the reported RNA-seq data, we selected eight candidate genes (CDC25A, CDT1, CENPM, MCM4, MYBL2, MYC, TERT, and TSPOAP1) that displayed no less than 1.5-fold level changes in the JQ1-induced transcriptional downregulation upon ENL-depletion. We then incubated MOLM-13 cells with XL-13m and JQ1 and analyzed them by real time (RT)-qPCR to monitor the transcription level changes of the selected genes. The treatment by either JQ1 or XL-13m alone moderately lowered the transcription levels of most candidate genes (Fig. 6c) . More importantly, the co-treatment of XL-13m and JQ1 significantly enhanced the transcriptional downregulation of all eight candidate genes caused by either XL-13m or JQ1 alone (Fig. 6c) . In addition to SEC, ENL also directly interacts with histone methyltransferase DOT1L. It has been recently reported that ENL and DOT1L collaboratively regulate transcription programs responsible for the maintenance of MLL-rearranged leukemia 25 . In light of this discovery, we treated the MOLM-13 cells with XL-13m alone or in combination with DOT1L inhibitor EPZ-5676 and performed RT-qPCR to analyze the transcription level of MYC and HOXA9, two well-characterized genes promoting leukemogenesis. The cotreatment of XL-13m and EPZ-5676 led to an enhanced effect on the transcription suppression of MYC and HOXA9 (Fig. 6d) . Our For all the competitive photo-cross-linking assays, the photo-H3K9/27cr-labeled proteins were conjugated to rhodamine-N 3 and visualized by in-gel fluorescence scanning. The fluorescence intensity of each band was quantified by ImageJ. All curves were normalized between 100% and 0% at the highest and lowest fluorescence intensities, respectively. Data are reported as mean of two independent experiments. For the chemical structure of photo-H3K27cr, see Supplementary Fig. 6a . Uncropped gels are provided in Supplementary Fig. 12 .
results, in mutual complement with recent studies on ENL depletion or loss-of-function mutation 24, 25 , suggest a synergistic effect of ENL YEATS inhibition with BET and DOT1L inhibition in attenuating oncogene transcription in acute leukemia.
Discussion
Chemical inhibitors of histone PTM 'readers' are valuable tools for elucidating regulatory mechanisms and functions of their target proteins 16, 35, 36 . Although the YEATS domains were found to recognize histone Kcr marks [20] [21] [22] [23] , inhibitors targeting this new class of 'readers' have been lacking. In this study, we developed peptide-based inhibitors of YEATS domains by targeting a unique π -π -π stacking in the YEATS-Kcr recognition with expanded π systems to maximize the stacking interaction. The inhibitors carrying a 2-furancarbonyl (for example, XL-07 and XL-07i) and a 5-oxazolecarbonyl (for example, XL-13 and XL-13a) at the lysine side chain bound to AF9 and ENL YEATS domains with largely enhanced binding affinities (Figs. 2  and 4) . Although π stacking is commonly regarded as a relatively weak noncovalent interaction, it is frequently present at 'hot spots' of protein interfaces 37, 38 . Our study demonstrates that targeting π stacking is a feasible strategy for the development of inhibitors against protein-protein interactions. This strategy can be readily extended to develop inhibitors for other YEATS domains including YEATS2 and GAS41, whose biological significance as Kac and Kcr 'readers' remains poorly understood.
The YEATS domains of AF9 and ENL share a high structural similarity. In this study, we developed the selective inhibitors XL-13a and XL-13m for AF9 and ENL YEATS domains, respectively. Although both inhibitors carry oxazole carbonylated lysine that would occupy the protein Kac/Kcr-binding pockets, there are subtle differences in the sequences and lengths of the peptide-based inhibitor N-terminal fragments. As the N-terminal fragments of the inhibitors extend to the L8 loop region of the YEATS domains (Fig. 3) , the differences in the protein-inhibitor interactions at this region may account for the selectivity of the inhibitors toward AF9 and ENL. Interestingly, a recent study identified the mutations in the L8 loop of ENL YEATS in Wilms tumor 39 , an embryonal neoplasm of the childhood kidney. The mutations were shown to alter the binding affinities of the ENL YEATS toward histone H3K9/27ac marks. Further characterizations suggested that the ENL YEATS mutations play an important role in the etiology of a subset of Wilms tumor. Based on our current study, it is highly possible that inhibitors that selectively target the ENL mutants in Wilms tumor can be developed by varying the residues in contact with the L8 loop. Such inhibitors would be useful to probe the roles of ENL during early renal development and pathogenesis of the Wilms tumor.
The epigenetic landscape of a cell is commonly orchestrated by combinatory actions of multiple epigenetic proteins 40, 41 . In MLL-translocated leukemias, the histone methyltransferase DOT1L is commonly recruited by the MLL-fusion proteins (for example, MLL-AF4 or MLL-AF9), leading to abnormal active transcription of multiple oncogenes by installing the H3K79 methylation marks at the targeted loci [42] [43] [44] . These studies demonstrated the potential of DOT1L inhibition in the disruption of leukemogenic transcription programs. At the same time, histone methylation and acetylation are known to interplay in regulating malignant transcriptional programs. For example, DOT1L, via catalyzing H3K79 methylation, facilitates the recruitment of the acetyltransferase EP300, which in turn acetylates the lysine residues on the N-terminal tail of histone H4 (for example, H4K5) and enables the binding of BRD4 to chromatin for activation of gene expression at critical MLL-fusion proteindriven oncogenes 45 . These studies demonstrated the therapeutic potential of combinatorial modulation of histone methylation and acetylation against MLL-translocated leukemias. In recent studies, the functional cooperation between ENL and BRD4 or DOT1L was also observed in the regulation of leukemogenic transcription programs 24, 25 , suggesting that ENL YEATS inhibition is likely a new therapeutic strategy for the treatment of acute leukemia. In this study, we demonstrated that exposure of cells to XL-13m, an ENL YEATS-selective inhibitor, diminished the occupation of ENL on a series of genes related to leukemia initiation and suppressed their transcription. We further showed that XL-13m synergized with BET and DOT1L inhibitors, leading to the enhanced downregulation of a set of genes that were essential for leukemogenesis and leukemia maintenance. Therefore, evaluation of the anti-leukemia activity of XL-13m and other developed ENL-inhibitors will be the important next step. Though the commonly poor cell permeability of peptide-based inhibitors may hinder their application in cell-based investigations, such limitation can be overcome by a couple of strategies, such as encapsulation of inhibitors using liposomes 46 . The inhibitors developed in this study also provide the opportunity to investigate unknown roles played by ENL in a YEATSdependent way. ENL, or its paralog AF9, is a key component of the SEC, a multiprotein complex involved in the regulation of rapid transcription induction 47 . A study on the SEC-dependent transcription revealed that the YEATS domain targeted the SEC to chromatin through direct binding with the RNA polymerase II (Pol II)-associated factor complex (PAFc) 48 . It is therefore interesting to examine whether the YEATS-PAFc interaction could be dependent on the capability of YEATS to recognize Kac and Kcr marks on the PAFc. In a recent study, histone H3K9ac was found to mediate the recruitment of SEC onto chromatin to facilitate the release of paused Pol II at selected gene promoters 49 . Although a solid evidence is lacking, it is likely that the YEATS domain, as a H3K9ac 'reader' , is responsible for the SEC recruitment. We anticipate that the use of the inhibitors developed in this study would provide new evidences to dissect the mechanisms underlying the recruitment of SEC onto chromatin.
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Methods
General. Photo-cross-linking was performed with ENF-260C/FE hand-hang UV lamp (Spectroline). In-gel fluorescence scanning was performed using a Typhoon 9410 variable mode imager from GE Healthcare Life Sciences (excitation 532 nm, emission 580 nm). Immunoblotting membranes were visualized by MyECL Imager from Thermo Scientific. All images were processed by ImageJ software (National Institutes of Health), and contrast was adjusted appropriately. ITC experiments were performed with a MicroCal iTC200 titration calorimeter (MicroCal). IC 50 . MOLM-13 cells stably expressing Flag-tagged ENL was generated as previously described 24 . HeLa S3 and HEK 293 T cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μ g/mL streptomycin. MOLM-13 (Flag-ENL), MV4;11 and HEL cells were cultured in RPMI 1640 medium with 10% FBS, 100 U/mL penicillin, and 100 μ g/mL streptomycin. Blasticidin (10 μ g/mL) was further supplied into MOLM-13 (Flag-ENL) cell culture medium to maintain the expression of Flag-ENL. Cells were maintained in a humidified 37 °C incubator with 5% CO 2 .
Preparation of nuclear extracts. The harvested cells were suspended with buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , and 10 mM KCl. Freshly added 0.5 mM PMSF and 1 × Roche Complete EDTA-free protease inhibitors). Homogenized the suspension with Dounce homogenizer (B type pestle, 20 strokes) and incubated on ice for 10 min. Centrifuged for 15 min at 800 × g at 4 °C. The supernatant was discarded. The pellet was further centrifuged for 15 min at 21,000 × g at 4 °C. The supernatant was discarded. The resulting pellet was resuspended with buffer B (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , and 0.2 mM EDTA, as well as freshly added 0.5 mM PMSF and 1 × Roche Complete EDTA-free protease inhibitors). Homogenized the suspension with Dounce homogenizer (B type pestle, 20 strokes) and incubated on ice for 30 min on ice. After centrifugation at 21,000 × g for 30 min at 4 °C, the supernatant was collected as nuclear extracts and dialyzed in binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 0.1% tween-20, 20% glycerol, and 0.5 mM PMSF) overnight at 4 °C. Protein concentration was measured by Bradford (Bio-Rad).
Photo-cross-linking. The probes in the absence or presence of different concentrations of competitors were incubated with recombinant proteins (5 or 20 ng/μ L) or nuclear extracts (1 mg/mL) in binding buffer (50 mM HEPES, 150 mM NaCl, 2 mM MgCl 2 , 0.1% Tween-20, 20% glycerol, pH 7.5, with or without 50 ng/μ L BSA) for 10 min at 4 °C. Then, the samples were irradiated at 365 nm using UV lamp for 20 min in 96-well (recombinant proteins, 75 μ L each well) or 12-well plate (nuclear extracts, 1 mL each well) on ice.
Cu(i)-catalyzed azide-alkyne cycloaddition/'Click' chemistry. To the prepared photo-cross-linking samples, we added 100 μ M rhodamine-N 3 for in-gel fluorescence (10 mM stock in DMSO) or biotin-N 3 for pulldown (5 mM stock in DMSO), followed by 1 mM TCEP (freshly prepared 50 mM stock in H 2 O) and 100 μ M TBTA (10 mM stock in DMSO); finally, the reactions were initiated by the addition of 1 mM CuSO 4 (freshly prepared 50 mM stock in H 2 O). The reactions were incubated for 1 h at room temperature (22 to 25 ºC) with regular vortexing. The reactions were quenched by adding 5 volumes of ice-cold acetone and placed at − 20 °C overnight to precipitate proteins.
In-gel fluorescence scanning. Samples after protein precipitation were centrifuged at 6,000 × g for 5 min at 4 °C. The supernatant was discarded, and the pellet was washed with ice-cooled methanol twice and air-dried for 10 min. The proteins were resuspended in 1 × LDS sample loading buffer (Invitrogen) with 50 mM DTT and heated at 80 °C for 8 min. Samples were then resolved by SDS-PAGE. The labeled proteins were visualized by scanning the gel on a Typhoon 9410 variable mode imager (excitation 532 nm, emission filter 580 nm).
Isothermal titration calorimetry measurements. Experiments were performed at 25 °C on a MicroCal iTC200 titration calorimeter (MicroCal) in buffer (150 mM NaCl, 50 mM HEPES, 1 mM TCEP, pH 7.5). The reaction cell contained 200 μ L of 30− 100 μ M proteins, which was titrated with corresponding peptides (ten-fold higher than the protein concentration used). Each of the titration contained 17− 20 injections. For every first injection, the volume was 0.5 μ L. For the other injections, the volume was 2 μ L. The binding isotherm was fit with Origin 7.0 software package (OriginLab) using a single set of independent sites to determine the thermodynamic dissociation constants and stoichiometry.
Crystallization, data collection and structure determination. Prior to crystallization, AF9 (1-138) protein sample was mixed with XL-07i at a 1:2 molar ratio for about 2 h. The complex sample was then concentrated to ~8 mg/mL for use. Crystallization was performed under 4 °C via vapor diffusion method under the condition: 0.2 M ammonium sulfate, 0.1 M sodium citrate tribasic dihydrate, pH 5.6 and 25% (w/v) PEG4000. The crystals were briefly soaked in cryoprotectant solution containing the reservoir solution supplemented with 10% glycerol and flash-frozen in liquid nitrogen for data collection at 100 K. Diffraction data were collected at Shanghai Synchrotron Radiation Facility BL17U under cryo-conditions at 0.9791 Å. All diffraction images were indexed, integrated, and merged using the HKL2000 software package 52 . The structure was determined by molecular replacement using MOLREP 53 with the AF9 YEATS/H3K9ac structure (PDB code: 4TMP) as the search model and refined by the program PHENIX 54 with iterative model building by the program COOT 55 . Ramachandran Plot analysis revealed no outliers in backbone dihedral angle distribution for the refined structure; about 98.9% and 1.1% backbone dihedral angles were located to the favored and allowed regions, respectively. Detailed data collection and refinement statistics are summarized in Supplementary Table 1 . Structure figures were created using the PYMOL program (http://www.pymol.org/).
In silico modeling. The model of AF9 YEATS domain bound with XL-13a inhibitor was obtained using AF9 YEATS-XL-07i structure (PDB code: 5YYF) as the initial model and manually adjusted in COOT.
Cellular thermal shift assay (CETSA).
The CETSA was performed essentially following the published protocol 31 . Briefly, MOLM-13 (Flag-ENL), MV4;11, or HEL cells were incubated with 50 μ M XL-13m for 12 h, and cells were washed with PBS three times and collected. The cell pellets were resuspended in PBS with 1 × Roche Complete EDTA-free protease inhibitors (approximately 3 million cells in 100 μ L). The cells (100 μ L per tube) were then heated at indicated temperatures for 3 min in a thermal cycler (Bio-Rad) and then incubated at room temperature for 3 min. Samples were frozen in liquid nitrogen, and subjected to two freeze-thaw cycles to lyse the cells. The cell lysate was centrifuged at 20,000 × g at 4 °C for 20 min, and the resulting supernatant were subjected to immunoblotting analysis.
Immunoblotting. Protein samples were resolved by SDS-PAGE and transferred onto a PVDF membrane (GE Healthcare). The membrane was blocked by 5% nonfat milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBST) for 1 h at room temperature and incubated overnight with primary antibody in blocking buffer (5% bovine serum albumin in TBST) at 4 °C. The membrane was then washed by TBST for three times and incubated with secondary antibodies (Santa Cruz Biotechnologies) in TBST for 1 h at room temperature. After washing by TBST for three times, the proteins were visualized with SuperSignal west dura extended duration substrate using MyECL Imager system (Thermo Fisher Scientific).
Chromatin immunoprecipitation (ChIP).
Chromatin immunoprecipitation was performed as previously reported 25 with minor modifications. Approximate 20 million MOLM-13 (Flag-ENL) cells were treated with or without 50 μ M XL13m for 24 h. Cells were then cross-linked for 10 min at room temperature, by direct addition of 1/10 volume of 10 × crosslinking solution (11% formaldehyde, 50 mM HEPES pH 7.3, 100 mM NaCl, 1 mM EDTA, and 0.5 mM EGTA) into culture medium. Cross-linking was quenched by 0.125 M glycine for 5 min at room temperature, and cells were washed three times with PBS. Cell pellets
